Company Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States.
It offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. The company also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency.
The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products.
Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2006 |
| IPO Date | Mar 28, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Michael Amoroso |
Contact Details
Address: 302 East Pettigrew Street, Suite A-100 Durham, North Carolina 27701 United States | |
| Phone | 919 314 5512 |
| Website | precisionbiosciences.com |
Stock Details
| Ticker Symbol | DTIL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001357874 |
| CUSIP Number | 74019P108 |
| ISIN Number | US74019P2074 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Naresh Tanna | Chief of Staff to Chief Executive Officer and Head of Investor Relations |
| Michael Amoroso | President, Chief Executive Officer and Director |
| Dr. Jefferson J. Smith Ph.D. | Co-Founder and Chief Research Officer |
| John Alexander Kelly R.Ph. | Chief Financial Officer and Principal Accounting Officer |
| Dr. Cassie Gorsuch Ph.D. | Chief Scientific Officer |
| Dario Scimeca J.D. | General Counsel and Secretary |
| Juli Blanche | Chief People Officer |
| Cindy Atwell | Chief Development and Business Officer |
| Neil Leatherbury M.S. | Senior Vice President and Head of Chemistry, Manufacturing and Controls |
| Dr. Murray Abramson M.D., M.P.H. | Senior Vice President and Head of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2025 | ARS | Filing |
| Apr 15, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 26, 2025 | SCHEDULE 13G | Filing |
| Mar 26, 2025 | 424B5 | Filing |
| Mar 26, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 144 | Filing |
| Mar 18, 2025 | SCHEDULE 13G | Filing |